For Orphan Drugs, The Regulatory Challenge Is Just The Beginning
Executive Summary
After an orphan drug gets past the regulatory challenges, it must face commercial challenges as well. During a panel review on Dyax's HAE candidate Kalbitor (ecallantide), committee members discussed the need for a solid risk management plan and educational effort for orphan drugs and diseases.